Briacell Therapeutics Corp. income statement BCTXZ

Annual Quarterly

It recorded a net loss of $34.9 million. Diluted earnings per share were -$6.97.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2026
Jul 31, 2026
FY 2025
Jul 31, 2025
FY 2024
Jul 31, 2024
FY 2023
Jul 31, 2023
FY 2022
Jul 31, 2022
Research and development
29
+37.4%
21
-21.7%
27
+77.2%
15
+91.2%
8
+296.9%
Selling, general and administrative
7
+14.9%
6
-3.5%
6
-22.5%
8
+9.2%
7
+46.7%
Operating income
-36
-32.5%
-27
+18.4%
-33
-43.2%
-23
-52.2%
-15
Pretax income
35
+33.0%
27
+438.5%
5
-75.7%
20
+175.6%
-27
Net income
-35
-32.7%
-26
-449.1%
-5
+76.4%
-20
+24.4%
-27
Basic EPS
-6.97
+88.8%
-62.19
-42.4%
-43.68
-3260.0%
-1.30
+24.9%
-1.73
Diluted EPS
-6.97
+88.8%
-62.19
-42.4%
-43.68
-3260.0%
-1.30
—
Weighted average shares, basic
5
+1084.3%
0
+285.7%
0
-99.3%
16
+0.8%
15
Weighted average shares, diluted
5
+1084.3%
0
+285.7%
0
-99.3%
16
—
Other measures
Depreciation and amortization
0
+13.9%
0
+33.1%
0
—
0
+0.1%
EBITDA
-36
-32.6%
-27
+18.5%
-33
—
-15
Interest coverage
-1,216.77x
-735.68x
—
—
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
BCTX (Nasdaq), BCTXL (Nasdaq), BCTXZ (Nasdaq)
Fiscal year ends
July 31
Incorporated in
British Columbia, Canada
Headquarters
West Vancouver, British Columbia, Canada
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1610820
Former names
Ansell Capital Corp. (until Jun 20, 2014)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.